Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Pi Therapeutics logo — Pioneering new therapies targeting the ubiquitin-proteasome...

Pi Therapeutics

Pioneering new therapies targeting the ubiquitin-proteasome system to combat cancer.

Founded 2015 Series B Total: $19.70M Biotechnology

General Information

Company Name Pi Therapeutics
Founded Year 2015
Industries Biotechnology
Funding Stage Series B
Social

Get notified when Pi Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Pi Therapeutics

Pi Therapeutics is a biopharmaceutical company dedicated to pioneering new therapies targeting the ubiquitin-proteasome system (UPS) to combat cancer. Since March 2015, the company has been operational within the FutuRx biotech accelerator located in Ness Ziona, Israel. The latest significant financial backing came in the form of a $19.70M Series B investment at 29 May 2019, with key investors including Pontifax, GHS Fund, RMGP, GF Securities, CBG Asset Management, and Arkin Bio Ventures. Notable backers of the company include Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, and the Israel Innovation Authority. Pi Therapeutics is focused on discovering and developing innovative cancer treatments by creating new first-in-class drugs targeting the UPS for cancer treatment.

Taxonomy: biopharmaceutical company, cancer treatments, drug discovery, Ubiquitin-proteasome system, cancer therapy, Takeda Pharmaceuticals, Johnson & Johnson Innovation, OrbiMed Israel Partners, Pontifax, Israel Innovation Authority, FutuRx biotech accelerator, Israel, oncology, venture capital, startups

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor Investor
•••• •••• 		29 May 2019

Pi Therapeutics Alternatives & Competitors

Pi Therapeutics vs
Immunicon
Immunicon

Pioneering cell-based diagnostic solutions to empower physicians with timely and accurate cancer ins...

Series F
Biotechnology, Health Care
Pi Therapeutics vs
SYNCSENSE® - VR for Rehab
SYNCSENSE® - VR for Rehab Denmark

Activating inactive patients with VR // Provided for hospitals, rehab, care & neuro centers

6 employees
Health Care, Medical Devices
Pi Therapeutics vs
Rapport Therapeutics
Rapport Therapeutics United States

Precision medicines to match the complexity of the human brain.

IPO
102 employees
Biotechnology, Health Care
Compare Pi Therapeutics vs Rapport Therapeutics

FAQ About Pi Therapeutics

Pioneering new therapies targeting the ubiquitin-proteasome system to combat cancer.
Pi Therapeutics was founded in 2015.
Pi Therapeutics operates in the following industries: Biotechnology.
Pi Therapeutics has completed 1 funding round, raising a total of $19.70M. The latest funding stage is Series B.
Top alternatives and competitors to Pi Therapeutics include Immunicon, SYNCSENSE® - VR for Rehab, Rapport Therapeutics, Aptevo Therapeutics Inc, Infiniplex. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pi Therapeutics and Immunicon are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Pi Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy